Cristina Corina Clement

Dr. Cristina Corina Clement

Weill Cornell Medicine, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Developmental Cell
Verified
Journal Article
Closed access
RSRanjit Sahu
Ranjit Sahu
SKSusmita Kaushik
Susmita Kaushik
Cristina Corina ClementCristina Corina Clement
Cristina Corina Clement
ECElvira S. Cannizzo
Elvira S. Cannizzo
BSBrian Scharf
Brian Scharf
LSLaura Santambrogio
Laura Santambrogio

1 October 2006 in Cancer Cell
Verified
Journal Article
Closed access
HHHaley Hieronymus
Haley Hieronymus
JLJustin Lamb
Justin Lamb
KRKenneth N. Ross
Kenneth N. Ross
XPXiao P. Peng
Xiao P. Peng
Cristina Corina ClementCristina Corina Clement
Cristina Corina Clement
TGTodd R. Golub
Todd R. Golub

22 April 2021 in Cell
Verified
Journal Article
Closed access
MBMathieu Bourdenx
Mathieu Bourdenx
AMAdrián Martín-Segura
Adrián Martín-Segura
ASAurora Scrivo
Aurora Scrivo
JRJose A. Rodriguez-Navarro
Jose A. Rodriguez-Navarro
SKSusmita Kaushik
Susmita Kaushik
ACAna Maria Cuervo
Ana Maria Cuervo

1 October 2011 in Journal of Proteomics
Verified
Journal Article
Closed access
ECElvira S. Cannizzo
Elvira S. Cannizzo
Cristina Corina ClementCristina Corina Clement
Cristina Corina Clement
RSRanjit Sahu
Ranjit Sahu
CFCarlo Follo
Carlo Follo
LSLaura Santambrogio
Laura Santambrogio

19 May 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
ECEloisi Caldas-Lopes
Eloisi Caldas-Lopes
LCLeandro Cerchietti
Leandro Cerchietti
JAJames H. Ahn
James H. Ahn
Cristina Corina ClementCristina Corina Clement
Cristina Corina Clement
ARAna Robles
Ana Robles
GCGabriela Chiosis
Gabriela Chiosis
Triple-negative breast cancers (TNBCs) are defined by a lack of expression of estrogen, progesterone, and HER2 receptors. Because of the absence of identified targets and targeted therapies, and due to a heterogeneous molecular presentation, treatment guidelines for patients with TNBC include only conventional chemotherapy. Such treatment, while effective for some, leaves others with high rates of early relapse and is not curative for any patient with metastatic disease. Here, we demonstrate that these tumors are sensitive to the heat shock protein 90 (Hsp90) inhibitor PU-H71. Potent and durable anti-tumor effects in TNBC xenografts, including complete response and tumor regression, without toxicity to the host are achieved with this agent. Notably, TNBC tumors respond to retreatment with PU-H71 for several cycles extending for over 5 months without evidence of resistance or toxicity. Through a proteomics approach, we show that multiple oncoproteins involved in tumor proliferation, survival, and invasive potential are in complex with PU-H71-bound Hsp90 in TNBC. PU-H71 induces efficient and sustained downregulation and inactivation, both in vitro and in vivo, of these proteins. Among them, we identify downregulation of components of the Ras/Raf/MAPK pathway and G 2 -M phase to contribute to its anti-proliferative effect, degradation of activated Akt and Bcl-xL to induce apoptosis, and inhibition of activated NF-κB, Akt, ERK2, Tyk2, and PKC to reduce TNBC invasive potential. The results identify Hsp90 as a critical and multimodal target in this most difficult to treat breast cancer subtype and support the use of the Hsp90 inhibitor PU-H71 for clinical trials involving patients with TNBC.

1 March 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
CLClaire Lhuillier
Claire Lhuillier
NRNils-Petter Rudqvist
Nils-Petter Rudqvist
TYTakahiro Yamazaki
Takahiro Yamazaki
TZTuo Zhang
Tuo Zhang
MCMaud Charpentier
Maud Charpentier
SDSandra Demaria
Sandra Demaria
Neoantigens generated by somatic nonsynonymous mutations are key targets of tumor-specific T cells, but only a small number of mutations predicted to be immunogenic are presented by MHC molecules on cancer cells. Vaccination studies in mice and patients have shown that the majority of neoepitopes that elicit T cell responses fail to induce significant antitumor activity, for incompletely understood reasons. We report that radiotherapy upregulates the expression of genes containing immunogenic mutations in a poorly immunogenic mouse model of triple-negative breast cancer. Vaccination with neoepitopes encoded by these genes elicited CD8+ and CD4+ T cells that, whereas ineffective in preventing tumor growth, improved the therapeutic efficacy of radiotherapy. Mechanistically, neoantigen-specific CD8+ T cells preferentially killed irradiated tumor cells. Neoantigen-specific CD4+ T cells were required for the therapeutic efficacy of vaccination and acted by producing Th1 cytokines, killing irradiated tumor cells, and promoting epitope spread. Such a cytotoxic activity relied on the ability of radiation to upregulate class II MHC molecules as well as the death receptors FAS/CD95 and DR5 on the surface of tumor cells. These results provide proof-of-principle evidence that radiotherapy works in concert with neoantigen vaccination to improve tumor control.